Your browser doesn't support javascript.
loading
Janus kinase inhibitors: between prescription authorization and reimbursability.
Spinelli, F R; Conti, F; Caporali, R; Iannone, F; Cacciapaglia, F; Steering Committee Of The Italian Society Of Rheumatology, On Behalf Of The.
Afiliación
  • Spinelli FR; Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome. francescaromana.spinelli@uniroma1.it.
  • Conti F; Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome. fabrizio.conti@uniroma1.it.
  • Caporali R; Rheumatology Unit, Department of Clinical and Community Sciences, University of Milan, ASST Gaetano Pini-CTO, Milan. roberto.caporali@unimi.it.
  • Iannone F; Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro. florenzo.iannone@uniba.it.
  • Cacciapaglia F; Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro. fabio.cacciapaglia79@gmail.com.
  • Steering Committee Of The Italian Society Of Rheumatology OBOT; . abrizio.conti@uniroma1.it.
Reumatismo ; 75(4)2023 Dec 19.
Article en En | MEDLINE | ID: mdl-38115771
ABSTRACT
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reumatología / Inhibidores de las Cinasas Janus Límite: Humans Idioma: En Revista: Reumatismo Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reumatología / Inhibidores de las Cinasas Janus Límite: Humans Idioma: En Revista: Reumatismo Año: 2023 Tipo del documento: Article